[go: up one dir, main page]

EP3199554A4 - Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii) - Google Patents

Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii) Download PDF

Info

Publication number
EP3199554A4
EP3199554A4 EP15843808.5A EP15843808A EP3199554A4 EP 3199554 A4 EP3199554 A4 EP 3199554A4 EP 15843808 A EP15843808 A EP 15843808A EP 3199554 A4 EP3199554 A4 EP 3199554A4
Authority
EP
European Patent Office
Prior art keywords
fviii
function
factor viii
coagulation factor
antibody capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15843808.5A
Other languages
German (de)
English (en)
Other versions
EP3199554A1 (fr
Inventor
Tomoyuki Igawa
Atsushi Muto
Takehisa Kitazawa
Tsukasa Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3199554A1 publication Critical patent/EP3199554A1/fr
Publication of EP3199554A4 publication Critical patent/EP3199554A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP15843808.5A 2014-09-26 2015-09-24 Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii) Pending EP3199554A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014197207 2014-09-26
PCT/JP2015/076854 WO2016047656A1 (fr) 2014-09-26 2015-09-24 Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii)

Publications (2)

Publication Number Publication Date
EP3199554A1 EP3199554A1 (fr) 2017-08-02
EP3199554A4 true EP3199554A4 (fr) 2018-07-18

Family

ID=55581180

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15843808.5A Pending EP3199554A4 (fr) 2014-09-26 2015-09-24 Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii)

Country Status (17)

Country Link
US (1) US11214623B2 (fr)
EP (1) EP3199554A4 (fr)
JP (2) JP6702877B2 (fr)
KR (1) KR102517509B1 (fr)
CN (1) CN107108746B (fr)
AR (1) AR102092A1 (fr)
AU (1) AU2015322662B2 (fr)
CA (1) CA2961968C (fr)
IL (1) IL251111B (fr)
MX (1) MX388728B (fr)
MY (1) MY192018A (fr)
NZ (1) NZ730611A (fr)
RU (1) RU2737145C2 (fr)
SG (1) SG11201702259RA (fr)
TW (1) TWI700300B (fr)
WO (1) WO2016047656A1 (fr)
ZA (1) ZA201701844B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
SG11201807765PA (en) 2016-04-28 2018-10-30 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
TW201836636A (zh) * 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 含有替代凝血因子ｖｉｉｉ功能之多特異性抗原結合分子之用於預防和／或治療凝血因子ｉｘ異常症的醫藥組合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN107449925A (zh) * 2017-09-22 2017-12-08 郑州大学第附属医院 一种用于凝血因子viii抑制物检测的缓冲液以及检测方法
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
MY202203A (en) * 2018-08-01 2024-04-17 Novo Nordisk As Improved procoagulant antibodies
WO2020128049A1 (fr) 2018-12-21 2020-06-25 Kymab Limited Anticorps bispécifique fixaxfx avec chaîne légère commune
WO2020153940A1 (fr) * 2019-01-22 2020-07-30 Clemson University Anticorps anti-élastine et méthodes d'utilisation
KR20230014719A (ko) 2020-05-22 2023-01-30 추가이 세이야쿠 가부시키가이샤 응고 제viii 인자(f.viii) 기능 대체 활성을 갖는 물질을 중화하는 항체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065611A1 (fr) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha Procede de selection par criblage d'une chaine legere d'anticorps
WO2014050926A1 (fr) * 2012-09-28 2014-04-03 中外製薬株式会社 Procédé d'évaluation de réaction de coagulation du sang
WO2016047652A1 (fr) * 2014-09-26 2016-03-31 公立大学法人奈良県立医科大学 Procédé pour mesurer la réactivité de fviii

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DK13485A (da) 1984-01-12 1985-07-13 Chiron Corp Hybridomacellelinie og monoklonalt antistof opnaaet ved hjaelp af en saadan cellelinie
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0332287A (ja) 1989-06-29 1991-02-12 Pioneer Electron Corp 記録媒体演奏装置
WO1991008770A1 (fr) 1989-12-11 1991-06-27 Immunomedics, Inc. Procede de ciblage par anticorps d'agents diagnostiques ou therapeutiques
TW212184B (fr) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
JPH06104071A (ja) 1991-08-30 1994-04-15 Jasco Corp 発熱体セラミックス溶接加工方法
EP1136556B1 (fr) 1991-11-25 2005-06-08 Enzon, Inc. Procédé pour produire de protéines multivalents de fixation de l'antigène
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
EP0660937A1 (fr) 1993-07-01 1995-07-05 Dade International Inc. Procede de preparatioin de plasma appauvri en facteur x
JP4361133B2 (ja) 1994-07-11 2009-11-11 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 血管系の特異的凝固のための方法および組成物
WO1996016673A1 (fr) 1994-12-02 1996-06-06 Chiron Corporation Methode permettant d'induire une reponse immunitaire avec un anticorps bispecifique
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5755446A (en) 1996-12-24 1998-05-26 United Technologies Corporation Seal apparatus between a shaft and a non-linear inner surface of a housing
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CN1073412C (zh) 1998-03-19 2001-10-24 中国科学院化学研究所 一种高分子微包囊的制备方法
EP1074842A1 (fr) 1999-07-21 2001-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Allo-anticorps catalytiques contre facteur VIII
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1299419A2 (fr) 2000-05-24 2003-04-09 Imclone Systems, Inc. Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
WO2002006838A1 (fr) 2000-07-17 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Methode de criblage d'un ligand dote d'une activite biologique
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (fr) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2824183B1 (fr) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production d'anticorps bispécifiques
EP1915176A4 (fr) 2005-07-15 2008-12-03 Univ Vermont Immunoessais ultrasensibles et anticorps pour detection du facteur viii sanguin
EP3056568B1 (fr) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
KR101625961B1 (ko) * 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
KR20100065158A (ko) 2007-08-23 2010-06-15 엘에프비 바이오테크놀로지스 인자 ⅷ의 ｃ1 도메인에 대향하는 저해 항체의 저해 활성을 중화시키는 항-개별특이형의 항체들
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2009203350B2 (en) * 2008-01-11 2014-03-13 Gene Techno Science Co., Ltd. Humanized anti-alpha9 integrin antibodies and the uses thereof
FR2933496B1 (fr) 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CN101906160A (zh) 2009-06-05 2010-12-08 苏州泽璟生物制药有限公司 一种抗人凝血因子ⅷ单克隆抗体及其制备方法和用途
EP2332994A1 (fr) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
ES2777901T3 (es) 2009-12-25 2020-08-06 Chugai Pharmaceutical Co Ltd Método de modificación de polipéptidos para purificar multímeros polipeptídicos
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
DK2591006T3 (da) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
PL2822587T3 (pl) 2012-03-08 2016-07-29 Hoffmann La Roche Preparat przeciwciała abeta
CA2942654A1 (fr) * 2013-03-15 2014-09-18 Bullet Biotechnology, Inc. Vaccins a particules de type viral multivalents specifiques et leurs utilisations
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
CN108472360B (zh) 2015-04-10 2023-01-17 阿迪马布有限责任公司 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
CN107454906B (zh) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
SG11201807765PA (en) 2016-04-28 2018-10-30 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
TW201836636A (zh) 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 含有替代凝血因子ｖｉｉｉ功能之多特異性抗原結合分子之用於預防和／或治療凝血因子ｉｘ異常症的醫藥組合物
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065611A1 (fr) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha Procede de selection par criblage d'une chaine legere d'anticorps
WO2014050926A1 (fr) * 2012-09-28 2014-04-03 中外製薬株式会社 Procédé d'évaluation de réaction de coagulation du sang
EP2902787A1 (fr) * 2012-09-28 2015-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé d'évaluation de réaction de coagulation du sang
WO2016047652A1 (fr) * 2014-09-26 2016-03-31 公立大学法人奈良県立医科大学 Procédé pour mesurer la réactivité de fviii
EP3199952B1 (fr) * 2014-09-26 2022-11-02 Chugai Seiyaku Kabushiki Kaisha Procédé pour mesurer la réactivité de fviii

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A MUTO ET AL: "Suppor ting Infor mation Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation", 1 February 2014 (2014-02-01), XP055572716, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111/jth.12474&file=jth12474-sup-0001-Supportinginforamtion.pdf> [retrieved on 20190321] *
See also references of WO2016047656A1 *

Also Published As

Publication number Publication date
CA2961968A1 (fr) 2016-03-31
CN107108746B (zh) 2021-06-08
JPWO2016047656A1 (ja) 2017-07-13
US20170275376A1 (en) 2017-09-28
MX2017003693A (es) 2017-06-26
US11214623B2 (en) 2022-01-04
IL251111B (en) 2021-03-25
RU2737145C2 (ru) 2020-11-25
KR102517509B1 (ko) 2023-04-04
ZA201701844B (en) 2021-10-27
MY192018A (en) 2022-07-22
EP3199554A1 (fr) 2017-08-02
IL251111A0 (en) 2017-04-30
AR102092A1 (es) 2017-02-01
CA2961968C (fr) 2023-01-24
MX388728B (es) 2025-03-20
AU2015322662A1 (en) 2017-04-06
AU2015322662B2 (en) 2020-12-10
WO2016047656A1 (fr) 2016-03-31
SG11201702259RA (en) 2017-04-27
BR112017005801A2 (pt) 2017-12-19
RU2017113732A3 (fr) 2019-01-30
JP2020108395A (ja) 2020-07-16
RU2017113732A (ru) 2018-10-23
TWI700300B (zh) 2020-08-01
CN107108746A (zh) 2017-08-29
KR20170064539A (ko) 2017-06-09
JP6702877B2 (ja) 2020-06-03
TW201619201A (zh) 2016-06-01
NZ730611A (en) 2021-12-24

Similar Documents

Publication Publication Date Title
EP3199554A4 (fr) Anticorps pour neutralisation de substance possédant une activité de substitution de fonction de facteur viii de la coagulation (fviii)
EP3127357B8 (fr) Système de vie
IL246661B (en) Human antibodies to pd–l1
EP3236772A4 (fr) Procédés permettant de purifier des protéines recombinantes
EP3240410A4 (fr) Utilisation de picolinamides en tant que fongicides
EP3104881A4 (fr) Réduction sélective de protéines
EP3240571A4 (fr) Formulation d&#39;anticorps thérapeutiques aglycosylés
EP3116898A4 (fr) Utilisation de la protéine m013 exprimée par un vecteur aav comme agent thérapeutique anti-inflammatoire
EP3101132A4 (fr) Anticorps humain anti-transthyrétine
EP2983476A4 (fr) Formulations et procédés pour le contrôle des espèces envahissantes
EP2985005A4 (fr) Seringue pour animal présentant une structure améliorée
EP3229814A4 (fr) Co-cristal de dapagliflozin et d&#39;acide citrique
EP3139956A4 (fr) Méthodes d&#39;utilisation d&#39;anticorps anti-ang2
EP3095439A4 (fr) Composition d&#39;émulsion pour la peau
EP3178923A4 (fr) Utilisation d&#39;une protéine susd2 à titre de marqueur
HUE045746T2 (hu) Eljárás fûszerkészítmények elõállítására
EP3145533B8 (fr) Compositions destinées à favoriser la cicatrisation des plaies
IL277377B (en) Prohemostatic proteins for the treatment of bleeding
EP3193904A4 (fr) Dipeptidomimetiques en tant qu&#39;inhibiteurs des immunoproteasomes humains
EP3183359A4 (fr) Sélectivité efficace des protéines recombinées
EP3207794A4 (fr) Dispositif de marche/arrêt pour dispositif de traction
AU2014901383A0 (en) Control of protein activity
HK1230937A1 (en) Human antibodies to middle east respiratory syndrome -coronavirus spike protein
EP3302067A4 (fr) Utilisation de protéines pour lutter contre les mollusques
HK1235665A1 (en) Methods of using anti-ang2 antibodies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/10 20060101ALI20180213BHEP

Ipc: C12N 15/09 20060101ALI20180213BHEP

Ipc: C07K 16/00 20060101ALI20180213BHEP

Ipc: C12N 1/21 20060101ALI20180213BHEP

Ipc: C12N 1/19 20060101ALI20180213BHEP

Ipc: C07K 16/42 20060101AFI20180213BHEP

Ipc: C12P 21/08 20060101ALI20180213BHEP

Ipc: C12N 1/15 20060101ALI20180213BHEP

Ipc: C07K 16/36 20060101ALI20180213BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20180613BHEP

Ipc: C12N 15/09 20060101ALI20180613BHEP

Ipc: C07K 16/42 20060101AFI20180613BHEP

Ipc: C12N 5/10 20060101ALI20180613BHEP

Ipc: C12P 21/08 20060101ALI20180613BHEP

Ipc: C07K 16/36 20060101ALI20180613BHEP

Ipc: C12N 1/19 20060101ALI20180613BHEP

Ipc: C12N 1/15 20060101ALI20180613BHEP

Ipc: C12N 1/21 20060101ALI20180613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190327